Gilead-Kite Oncology demonstrate dedication to advancing research for hard-to-treat blood cancers at 26th Annual Meeting of the European Hematology Association (EHA)

Study Name, Area of Focus and Presentation Number

Abstract Title and Primary Author

Oral Sessions

ZUMA-3: Acute Lymphoblastic Leukemia (ALL)

#S117

Phase 2 Results of the ZUMA-3 Study Evaluating KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL). Shah, BD et al.

ZUMA-5: Non-Hodgkin Lymphoma (NHL)

#S213

Outcomes in ZUMA-5 with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) who had the High-Risk Feature of Progression within 24 Months from Initiation of First Anti-CD20–Containing Chemoimmunotherapy (POD24). Jacobson, MD et al.

ePosters

ZUMA-1: Diffuse Large B Cell Lymphoma (DLBCL)

#EP495

Prophylactic Corticosteroid use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL). Olalekan O. Oluwole, MD et al. 

ZUMA-2: Mantle Cell Lymphoma (MCL)

#EP787

Outcomes with KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL) in ZUMA-2 who had Progression of Disease within 24 mo of Diagnosis (POD24). Wang, MD et al.

ZUMA-4: ALL & NHL

#EP341

ZUMA-4 Phase 1 Long-Term Results: KTE-X19 Chimeric Antigen Receptor T-Cell Therapy in Pediatric/Adolescent Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Wayne, AS et al.

ZUMA-5: NHL

#EP791

Updated Outcomes with Axicabtagene Ciloleucel (axi-cel) Retreatment (reTx) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) in ZUMA-5. Chavez, JC et al.

Health Economics and Outcomes Research (HEOR) ZUMA-1: DLBCL

#EP1167

ZUMA-1 Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs Tisagenlecleucel for the Management of Diffuse Large B-Cell Lymphoma in Spain. Bastos-Oreiro, M et al.

HEOR ZUMA-2: MCL

#EP786

ZUMA-2 KTE-X19 versus Standard of Care for Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with Bruton Tyrosine Kinase Inhibitors: Real-World Evidence from Europe. Hess, G. et al.

HEOR ZUMA-3: ALL

#EP366

ZUMA-3 Heterogeneity of Treatment Response Definitions in Refractory/Relapse Adult Acute Lymphoblastic Leukemia (R/R ALL): Findings from a Systematic Literature Review (SLR) of Clinical Trials Keeping, S et al.

Online publication

Magrolimab + Azacitidine: Myelodysplastic Syndrome

#PB1624

Magrolimab + Azacitidine Versus Azacitidine + Placebo In Untreated, Higher-risk (Hr) Myelodysplastic Syndrome: The Phase 3, Randomized, Enhance Study. Trial In Progress. Garcia-manero G, et al.

European Manufacturing

#PB1445

Manufacturing Commercial Axicabtagene Ciloleucel (Axi-Cel) for European Patients: A 2-Year Retrospective Analysis.
Louis van der Wiel, Dominique Tonelli et al.

HEOR ZUMA-3: ALL

#PB1735

ZUMA-3 Health-Related Quality of Life Among refractory/relapsed B-precursor acute lymphoblastic leukemia patients treated with KTE-X19: Results from Phase 2 an open-label, multicenter trial (ZUMA-3).       Shah, B et al.

HEOR ZUMA-5 Follicular Lymphoma

#PB1571

ZUMA-5 Clinical Outcomes in Patients Relapsed/Refractory After ≥ 2 Prior Lines of Therapy for Follicular Lymphoma: A Systematic Literature Review and Meta-Analysis. Kanters, S et al.